VSTM:NSD-Verastem Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.39

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

0.51M

Avg Analyst Target

USD 4.67 (+1,096.58%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


VSTM Stock Forecast & Price:
Based on the Verastem Inc stock forecasts from 3 analysts, the average analyst target price for Verastem Inc is USD 4.67 over the next 12 months. Verastem Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Verastem Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Verastem Inc’s stock price was USD 0.39. Verastem Inc’s stock price has changed by -4.88% over the past week, +2.60% over the past month and -86.07% over the last year.

About Verastem Inc (VSTM:NSD)

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp tha ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GILD Gilead Sciences Inc

+0.84 (+0.98%)

USD106.90B 32.28 22.67
VRTX Vertex Pharmaceuticals Inc

-3.18 (-1.01%)

USD82.52B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

+0.87 (+0.12%)

USD81.59B 15.59 11.88
MRNA Moderna Inc

-0.41 (-0.23%)

USD68.99B 3.18 4.44
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-1.38 (-0.88%)

USD37.91B 3.79 1.71
GMAB Genmab AS

+0.34 (+0.77%)

USD29.03B 36.52 3.47
ALNY Alnylam Pharmaceuticals Inc

+4.23 (+2.03%)

USD25.76B N/A -27.59
SGEN Seagen Inc

-0.52 (-0.42%)

USD23.02B 55.02 -41.49
ARGX argenx NV ADR

-2.93 (-0.78%)

USD20.68B N/A -20.30

ETFs Containing VSTM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -80.98% 19% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.98% 19% F 14% F
Trailing 12 Months  
Capital Gain -85.45% 18% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.45% 18% F 13% F
Trailing 5 Years  
Capital Gain -89.32% 28% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.32% 27% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -6.15% 55% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.15% 55% F 30% F
Risk Return Profile  
Volatility (Standard Deviation) 65.29% 30% F 18% F
Risk Adjusted Return -9.41% 59% F 43% F
Market Capitalization 0.08B 45% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.36 61% D- 55% F
Price / Cash Flow Ratio -1.57 40% F 53% F
EV/EBITDA -0.12 38% F 50% F
Management Effectiveness  
Return on Equity -92.71% 32% F 18% F
Return on Invested Capital -55.29% 47% F 22% F
Return on Assets -41.51% 26% F 10% F
Debt to Equity Ratio 0.28% 86% B 86% B
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.36 77% C+ 68% D+
Short Percent 2.13% 62% D- 53% F
Beta 0.62 75% C 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.